Product Information
ACYCLOVIR 5% OINTMENT is a generic product labeled by Sun Pharmaceutical Industries Inc., priced at $0.5221 per GM under NDC 51672136001. Its NADAC has been published 499 times since Mar 15, 2017.
FDA first approved this application on Dec 21, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Acyclovir market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
50 mg/g
Manufacturer
Sun Pharmaceutical Industries Inc.NDC
51672136001
Classification
Generic
Dosage Form
OINTMENT
Route
TOPICAL
Effective Date
9/23/2026
Active Ingredients
ACYCLOVIRApproval Type
Generic (ANDA)
FDA Application
ANDA205469FDA Approved
12/21/2016
TE Code
AB
On Market Since
12/21/2016
Pharmacological Classes
Price Statistics
The NADAC for ACYCLOVIR 5% OINTMENT has been published 499 times since Mar 15, 2017, and over the history we have for it it has declined 96.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5221 per GM |
|---|---|
| All-time high | $15.4571 (Mar 15, 2017) |
| All-time low | $0.4269 (Nov 20, 2024) |
| 52-week high | $0.6429 |
| 52-week low | $0.5153 |
| Median price | $1.0773 |
| Average price | $2.6439 |
| Largest weekly change | +46.7% (Aug 17, 2022) |
| Weeks tracked | 499 |
| Tracking since | Mar 15, 2017 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 34% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sun Pharmaceutical Industries Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Acyclovir market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ACYCLOVIR 5% OINTMENT?
The current National Average Drug Acquisition Cost (NADAC) for ACYCLOVIR 5% OINTMENT, manufactured by Sun Pharmaceutical Industries Inc., is $0.5221 per GM (NDC 51672136001), effective Sep 30, 2026.
How has the price of ACYCLOVIR 5% OINTMENT changed over time?
Over the history we have for it, the NADAC for ACYCLOVIR 5% OINTMENT has declined 96.6%. It has been tracked across 499 weekly CMS publications since Mar 15, 2017.
What are the highest and lowest recorded NADAC prices for ACYCLOVIR 5% OINTMENT?
Since Mar 15, 2017, the NADAC for ACYCLOVIR 5% OINTMENT has ranged from a low of $0.4269 (Nov 20, 2024) to a high of $15.4571 (Mar 15, 2017), with a median of $1.0773 per GM.
Are there cheaper alternatives to ACYCLOVIR 5% OINTMENT?
Yes. 5 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ACYCLOVIR 5% OINTMENT, is $0.3458 per GM — about 34% below ACYCLOVIR 5% OINTMENT.
Who manufactures ACYCLOVIR 5% OINTMENT?
ACYCLOVIR 5% OINTMENT (NDC 51672136001) is labeled by Sun Pharmaceutical Industries Inc., and CMS classifies it as a generic product.